IGI LABORATORIES, INC Form 8-K May 15, 2012

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (Date of earliest event reported): May 15, 2012

IGI LABORATORIES, INC.

(Exact name of registrant as specified in charter)

DELAWARE(State or Other Jurisdiction of Incorporation)

001-08568 (Commission file number)

01-0355758 (I.R.S. Employer Identification Number)

105 Lincoln Avenue

Buena, New Jersey 08310

(Address of principal executive offices)(Zip Code)

(856) 697-1441

(Registrant s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing	g is intended to simultaneously satisfy the filing obligation of	Σf
the registrant under any of the following provisions:		

[]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Results of Operations and Financial Condition.		
On May 15, 2012, IGI Laboratories, Inc. (the "Company") issued a press release announcing the Company's earnings		
for the first quarter ended March 31, 2012 and certain other information. A copy of the press release is attached hereto		
as Exhibit 99.1. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed		
filed for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that		

Section. The information in this Form 8-K shall not be incorporated by reference into any filing under the Securities

Act of 1933, except as shall otherwise be expressly set forth by specific reference in such filing.

Item 9.01.

Item 2.02.

Financial Statements and Exhibits.

(d) The following exhibits are furnished with this Form 8-K:

Exhibit No.

Description

99.1

Press Release of IGI Laboratories, Inc. dated May 15, 2012

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IGI LABORATORIES, INC.

Date: May 15, 2012 By: /s/ Jenniffer Collins
Name: Jenniffer Collins

Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit	
Number	Description of Exhibits

99.1 Press Release of IGI Laboratories, Inc. dated May 15, 2012